Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines

被引：9

作者：

Kyaw, Moe H. H. ^{[1
]}

Spinardi, Julia ^{[2
]}

Zhang, Ling ^{[3
]}

Oh, Helen May Lin ^{[4
]}

Srivastava, Amit ^{[5
]}

机构：

[1] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Gaithersburg, MD USA

[2] Pfizer Inc, Vaccine Med Affairs, Emerging Markets, Sao Paulo, Brazil

[3] Boehringer Ingelheim GmbH & Co KG, Real World Evidence Analyt Ctr Excellence, Ridgefield, CT USA

[4] Changi Gen Hosp, Dept Infect Dis, Singapore, Singapore

[5] Orbital Therapeut, Cambridge, MA 02139 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

BNT162b2; mRNA vaccine; COVID-19; heterologous booster; inactivated virus vaccine; effectiveness; CORONAVAC; DELTA;

D O I：

10.1080/21645515.2023.2165856

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Introduction of primary COVID-19 vaccination has helped reduce severe disease and death caused by SARS-CoV-2 infection. Understanding the protection conferred by heterologous booster regimens informs alternative vaccination strategies that enable programmatic resilience and can catalyze vaccine confidence and coverage. Inactivated SARS-CoV-2 vaccines are among the most widely used vaccines worldwide. This review synthesizes the available evidence identified as of May 26, 2022, on the safety, immunogenicity, and effectiveness of a heterologous BNT162b2 (Pfizer-BioNTech) mRNA vaccine booster dose after an inactivated SARS-CoV-2 vaccine primary series, to help protect against COVID-19. Evidence showed that the heterologous BNT16b2 mRNA vaccine booster enhances immunogenicity and improves vaccine effectiveness against COVID-19, and no new safety concerns were identified with heterologous inactivated primary series with mRNA booster combinations.

引用

页数：16

共 50 条

[21] Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine [J].

Basile, Kerri ;

Rockett, Rebecca J. ;

McPhie, Kenneth ;

Fennell, Michael ;

Johnson-Mackinnon, Jessica ;

Agius, Jessica E. ;

Fong, Winkie ;

Rahman, Hossinur ;

Ko, Danny ;

Donavan, Linda ;

Hueston, Linda ;

Lam, Connie ;

Arnott, Alicia ;

Chen, Sharon C-A ;

Maddocks, Susan ;

O'Sullivan, Matthew, V ;

Dwyer, Dominic E. ;

Sintchenko, Vitali ;

Kok, Jen .

VIRUSES-BASEL, 2022, 14 (09)

[22] Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents [J].

Mansanguan, Suyanee ;

Charunwatthana, Prakaykaew ;

Piyaphanee, Watcharapong ;

Dechkhajorn, Wilanee ;

Poolcharoen, Akkapon ;

Mansanguan, Chayasin .

TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (08)

[23] Anti-SARS-CoV-2 IgG antibodies in patients with or without SARS-CoV-2 infection after BNT162b2 vaccine booster [J].

Salvagno, G. L. ;

Henry, B. M. ;

Lippi, G. .

INFECTIOUS DISEASES NOW, 2022, 52 (06) :379-380

[24] Reactogenicity and immunogenicity of the intradermal administration of BNT162b2 mRNA vaccine in healthy adults who were primed with an inactivated SARS-CoV-2 vaccine [J].

Temtanakitpaisan, Yutthapong ;

Saengnipanthkul, Suchaorn ;

Sarakosol, Nataporn ;

Maskasame, Sasinapa ;

Mongkon, Siwawoot ;

Buranrat, Benjaporn ;

Thammawat, Sutthiwan ;

Patamatamkul, Samadhi ;

Nernsai, Pattaranit .

VACCINE: X, 2022, 12

[25] Comparison of antibody response to SARS-CoV-2 after two doses of inactivated virus and BNT162b2 mRNA vaccines in kidney transplant [J].

Seija, Mariana ;

Rammauro, Florencia ;

Santiago, Jose ;

Orihuela, Natalia ;

Zulberti, Catherine ;

Machado, Danilo ;

Recalde, Cecilia ;

Noboa, Javier ;

Frantchez, Victoria ;

Astesiano, Rossana ;

Yandian, Federico ;

Guerisoli, Ana ;

Morra, Alvaro ;

Cassinelli, Daniela ;

Coelho, Cecilia ;

de Aramburu, Belen ;

Gonzalez-Severgnini, Paulina ;

Moreno, Romina ;

Pippolo, Aldana ;

Lopez, Gabriela ;

Lemos, Monica ;

Somariva, Lorena ;

Lopez, Eliana ;

Fumero, Soledad ;

Orihuela, Carla ;

Rodriguez, Rosalia ;

Acuna, Gonzalo ;

Rabaza, Victoria ;

Perg, Nancy ;

Cordero, Rossana ;

Reisfeld, Cristina ;

Olivera, Paula ;

Montero, Paola ;

Nogueira, Cecilia ;

Nalerio, Catheryn ;

Orihuela, Sergio ;

Curi, Lilian ;

Burgstaller, Ema ;

Noboa, Oscar ;

Pritsch, Otto ;

Nin, Marcelo ;

Bianchi, Sergio .

CLINICAL KIDNEY JOURNAL, 2022, 15 (03) :527-533

[26] Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine [J].

Saresella, Marina ;

Piancone, Federica ;

Marventano, Ivana ;

Hernis, Ambra ;

Trabattoni, Daria ;

Invernizzi, Mattia ;

La Rosa, Francesca ;

Clerici, Mario .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[27] Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients [J].

Erol, Cigdem ;

Yalcin, Tugba Yanik ;

Sari, Nuran ;

Bayraktar, Nilufer ;

Soy, Ebru Ayvazoglu ;

Colak, Meric Yavuz ;

Azap, Ozlem ;

Arslan, Hande ;

Haberal, Mehmet .

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2021, 19 (12) :1334-1340

[28] Central diabetes insipidus: a late sequela of BNT162b2 SARS-CoV-2 mRNA vaccine? [J].

Ishay, Avraham ;

Shacham, Elena Chertok .

BMC ENDOCRINE DISORDERS, 2023, 23 (01)

[29] Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients [J].

Melin, Jan ;

Svensson, Maria K. ;

Albinsson, Bo ;

Winqvist, Ola ;

Pauksens, Karlis .

BMC IMMUNOLOGY, 2021, 22 (01)

[30] Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients [J].

Jan Melin ;

Maria K. Svensson ;

Bo Albinsson ;

Ola Winqvist ;

Karlis Pauksens .

BMC Immunology, 22

← 1 2 3 4 5 →